Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 2012-2019

  Luo, Y ^a   Zhao, Y T ^b   Verdo, A ^a   Qi, W G ^c   Zhang, Dai Fu ^a   Hu, B ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c The People s Hospital of Pu Dong New Area   (China)

Author keywords

Clopidogrel; Cytochrome P450 2C19 (CYP2C19); Genetics; Loss of Function Polymorphism; Stent Thrombosis

Indexed keywords

CLOPIDOGREL;

AGED; ARTICLE; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; CYTOCHROME P450 2C19 GENE; DOSE RESPONSE; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; STENT THROMBOSIS; WILD TYPE;

EID: 80155161850     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900548     Document Type: Article

References (29)

1. Cutlip DE, Windecker S, Mehran R, et al: Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
2. Gurbel PA, Bliden KP, Samara W, et al: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
3. Matetzky S, Shenkman B, Guetta V, et al: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
4. Bonello L, Dignat-George F, Camoin-Jau L, et al: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phos-phorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
5. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007; 120: 311-321.
6. Kim K, Park P, Hong S, et al: The effect of CYP2C19 polymorphism on the pharmaco-kinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 236-242.
7. Hulot JS, Bura A, Villard E, et al: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
8. Hagihara K, Kazui M, Kurihara A, et al: A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009; 37: 2145-2152.
9. Fontana P, Hulot JS, De Moerloose P, et al: Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007; 5: 2153-2155.
10. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355.
11. Gladding P, Webster M, Zeng I, et al: The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1: 612-619.
12. Giusti B, Gori AM, Marcucci R, et al: Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17: 1057-1064.
13. Hassan AK, Bergheanu SC, Stijnen T, et al: Late stent malapposition risk is higher after drugeluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2010; 31: 1172-1180.
14. Wenaweser P, Daemen J, Zwahlen M, et al: Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52: 1134-1140.
15. Trenk D, Hochholzer W, Fromm MF, et al: Cytochrome P450 2C19 681G. A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.
16. Yamada H, Dahl ML, Lannfelt L, et al: CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998; 54: 479-481.
17. Luo HR, Poland RE, Lin KM, et al: Genetic polymorphism of cytochrome P450 2c19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 2006; 80: 33-40.
18. Dandara C, Masimirembwa CM, Magimba A, et al: Genetic polymorphism of CYP2D6 and CYP2C19 in east-and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001; 57: 11-17.
19. Takakubo F, Kuwano A, Kondo I: Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics 1996; 6: 265-267.
20. Brandt JT, Close SL, Iturria SJ, et al: Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-2436.
21. Tantry US, Bliden KP, Wei C, et al: First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010; 3: 556-566.
22. Bouman HJ, van Werkum JW, Hackeng CM, et al: Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. Neth Heart J 2009; 17: 195-198.
23. Lau WC, Waskell LA, Watkins PB, et al: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
24. Gilard M, Arnaud B, Cornily JC, et al: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
25. Siller-Matula JM, Lang I, Christ G, et al: Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
26. Miao J, Liu R, Li Z: Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 2250-2251.
27. Lau WC, Gurbel PA: Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A4. Pharmacol Rev 2006; 23: 2691-2708.
28. Harmsze AM, van Werkum JW, Ten Berg JM, et al: CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010; 31: 3046-3053.
29. Sibbing D, Koch W, Gebhard D, et al: Cytochrome 2C19*17 allelic variant, platelet aggregation bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.